共 50 条
- [21] A bivalent Tim-3/PD-1 bispecific antibody for the treatment of PD-1 antibody resistant or refractory NSCLC.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Liu, JiajianLuan, Y.Deng, H.Wang, F.Wang, C.Zhang, Z.
- [22] Bispecific anti-PD-1/PD-L1 antibody CTX-8371 to promote cellular clustering and PD-1 shedding, antitumor activity and tolerability.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Albu, Diana I.Qin, YanWang, XianzheLi, VivianKim, TaegGong, BingSchuetz, ThomasKuklin, Nelly
- [23] In vivo characterization of anti-PD-1 antibody REGN2810 in human PD-1 knock-in miceCANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)Burova, ElenaAllbritton, OmairaPoueymirou, WilliamLai, VenusWaite, JanelleSkokos, DimitrisPapadopoulos, NicholasMurphy, DrewLowy, IsraelIoffe, EllaThurston, Gavin
- [24] Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory CancerFRONTIERS IN IMMUNOLOGY, 2021, 12Que, YiWang, JuanZhu, JiaLi, NaHuang, JuntingLu, SuyingSun, FeifeiZhang, LianZhen, ZijunZhang, LiCai, RuiqingGuo, HaixiaSun, XiaofeiZhang, Yizhuo
- [25] Immune checkpoint inhibitor (anti PD-1/PD-L1 antibody activity in dedifferentiated endometrial carcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Ono, RurikoNakayama, KentaroItamochi, HiroakiNakamura, KoheiSasamori, HirokiYamashita, HitomiIshibashi, TomokaIshikawa, MasakoOhnishi, KaoriMinamoto, ToshikoIida, KoujiIshikawa, NoriyoshiOtsuki, YoshiroKyo, Satoru
- [26] Combination therapy with anti-PD-1 or PD-1 antibody alone in pediatric patients with relapsed or refractory cancer.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Que, YiWang, JuanZhu, JiaLi, NaHuang, JuntingLu, SuyingSun, FeifeiZhang, LianZhen, ZijunZhang, LiCai, RuiqingGuo, HaixiaSun, XiaofeiZhang, Yizhuo
- [27] Discovery and pharmacological characterization of JNJ-63723283, an anti-programmed cell death protein-1 (PD-1) antibody that blocks PD-1 functionJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5Ferrante, CatherineDeAngelis, NikkiPowers, GordonSendecki, JocelynMillar, HillaryMattson, BethanyPizutti, DarleneMayer, Christina LourdesWang, WeirongBrittingham, RaymondWheeler, JohnBarone, LindaNanjunda, RupeshLacy, Eilyn R.Wu, Sheng-JiunLuo, JinquanZudaire, EnriquePackman, KathrynGeist, BrianTrouba, KevinLorenzi, Matthew V.Verona, Raluca I.
- [28] EFFICACY AND SAFETY OF ANTI-PD-L1 ANTIBODY IN NSCLC PATIENTS WHO PREVIOUSLY TREATED WITH ANTI PD-1 ANTIBODIES: PRELIMINARY STUDYRESPIROLOGY, 2018, 23 : 167 - 167Fujita, KoheiUchida, NaohiroYamamoto, YukiKanai, OsamuOkamura, MisatoNakatani, KoichiMio, Tadashi
- [29] The anti-LAG-3 antibody REGN3767 promotes immune activation in the tumor microenvironment and enhances antitumor activity of anti-PD-1 antibody REGN2810 in PD-1/LAG-3 humanized miceCANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)Burova, ElenaHalls, GaborAllbritton, OmairaZhang, WenOlson, WilliamMohrs, MarkusThurston, GavinIoffe, Ella
- [30] PPT1 inhibition enhances the antitumor activity of anti-PD-1 antibody in melanomaJCI INSIGHT, 2020, 5 (17)Sharma, GauravOjha, RaniNoguera-Ortega, EstelaRebecca, Vito W.Attanasio, JohnLiu, ShujingPiao, ShengfuLee, Jennifer J.Nicastri, Michael C.Harper, Sandra L.Ronghe, AmrutaJain, VaibhavWinkler, Jeffrey D.Speicher, David W.Mastio, JeromeGimotty, Phyllis A.Xu, XiaoweiWherry, E. JohnGabrilovich, Dmitry, IAmaravadi, Ravi K.